Stocks Health care CGON
NASDAQ · Health careCG Oncology, Inc. (CGON)
CG Oncology, Inc. brought in $6.2M of revenue over the twelve months to June 30, 2026, up 1,030.3% from a year earlier. It posted a net loss of $224.4M. In fiscal 2025 capital spending exceeded operating cash flow by $132.5M. At June 30, 2026 it held $19.6M in cash against $3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What CG Oncology, Inc. does
CG Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGON.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4M | -$161M | -$2.08 | -$132.5M |
| 2024 | $1.1M | -$88M | -$1.41 | -$78.9M |
| 2024 | $204K | -$48.6M | -$15.65 | n/a |
Latest SEC filings
What CG Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- August 6, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026
- May 26, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about CGON
What does CG Oncology, Inc. do?
CG Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGON.
Is CG Oncology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $224.4M on revenue of $6.2M.
How much revenue does CG Oncology, Inc. make?
Over the twelve months to June 30, 2026 CG Oncology, Inc. reported revenue of $6.2M. That is 1,030.3% more than a year earlier.
When did CG Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 21, 2026.
Similar companies
Follow CGON
Get an email when CG Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CGON: get an email when it filesWhere the numbers come from
Financial figures are the values CG Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.